Robbie Marcus
Stock Analyst at JP Morgan
(3.80)
# 720
Out of 5,005 analysts
165
Total ratings
54.05%
Success rate
7.74%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HTFL HeartFlow | Initiates: Overweight | $36 | $37.64 | -4.36% | 1 | Sep 2, 2025 | |
| COO The Cooper Companies | Maintains: Neutral | $76 → $66 | $70.46 | -6.33% | 6 | Aug 28, 2025 | |
| INSP Inspire Medical Systems | Downgrades: Neutral | $195 → $110 | $76.58 | +43.64% | 6 | Aug 5, 2025 | |
| EW Edwards Lifesciences | Maintains: Neutral | $80 → $85 | $77.07 | +10.29% | 5 | Jul 25, 2025 | |
| NPCE NeuroPace | Maintains: Overweight | $14 → $16 | $10.92 | +46.52% | 5 | May 14, 2025 | |
| CVRX CVRx, Inc. | Downgrades: Underweight | $15 → $7 | $8.71 | -19.63% | 6 | May 9, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Overweight | $128 → $105 | $100.78 | +4.19% | 6 | May 6, 2025 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $12 | $14.80 | -18.92% | 6 | May 6, 2025 | |
| CNMD CONMED | Maintains: Neutral | $70 → $58 | $48.13 | +20.51% | 7 | May 1, 2025 | |
| RXST RxSight | Downgrades: Underweight | $40 → $17 | $8.80 | +93.18% | 5 | Apr 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $120 | $84.21 | +42.50% | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $36 | $23.86 | +50.88% | 17 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $445 | $370.50 | +20.11% | 9 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $575 → $675 | $452.35 | +49.22% | 5 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $12 → $13 | $7.02 | +85.19% | 3 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $110 | $97.32 | +13.03% | 13 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $330 | $309.12 | +6.76% | 4 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $32 | $12.64 | +153.16% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $40 | $34.81 | +14.91% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $85 | $67.05 | +26.77% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $76.56 | +17.55% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $53 → $50 | $32.02 | +56.15% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $8 | $6.36 | +25.79% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $284 → $250 | $256.06 | -2.37% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $16 | $18.94 | -15.52% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $8.65 | -19.08% | 13 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $17 | $15.20 | +11.84% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $118 | $134.59 | -12.33% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $156 | $175.61 | -11.17% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $130 → $105 | $97.70 | +7.47% | 11 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $40 | $87.41 | -54.24% | 2 | May 5, 2020 |
HeartFlow
Sep 2, 2025
Initiates: Overweight
Price Target: $36
Current: $37.64
Upside: -4.36%
The Cooper Companies
Aug 28, 2025
Maintains: Neutral
Price Target: $76 → $66
Current: $70.46
Upside: -6.33%
Inspire Medical Systems
Aug 5, 2025
Downgrades: Neutral
Price Target: $195 → $110
Current: $76.58
Upside: +43.64%
Edwards Lifesciences
Jul 25, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $77.07
Upside: +10.29%
NeuroPace
May 14, 2025
Maintains: Overweight
Price Target: $14 → $16
Current: $10.92
Upside: +46.52%
CVRx, Inc.
May 9, 2025
Downgrades: Underweight
Price Target: $15 → $7
Current: $8.71
Upside: -19.63%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Overweight
Price Target: $128 → $105
Current: $100.78
Upside: +4.19%
Integra LifeSciences Holdings
May 6, 2025
Maintains: Underweight
Price Target: $24 → $12
Current: $14.80
Upside: -18.92%
CONMED
May 1, 2025
Maintains: Neutral
Price Target: $70 → $58
Current: $48.13
Upside: +20.51%
RxSight
Apr 4, 2025
Downgrades: Underweight
Price Target: $40 → $17
Current: $8.80
Upside: +93.18%
Mar 28, 2025
Initiates: Overweight
Price Target: $120
Current: $84.21
Upside: +42.50%
Feb 21, 2025
Maintains: Neutral
Price Target: $38 → $36
Current: $23.86
Upside: +50.88%
Jan 29, 2025
Maintains: Overweight
Price Target: $420 → $445
Current: $370.50
Upside: +20.11%
Jan 24, 2025
Maintains: Overweight
Price Target: $575 → $675
Current: $452.35
Upside: +49.22%
Dec 17, 2024
Upgrades: Neutral
Price Target: $12 → $13
Current: $7.02
Upside: +85.19%
Dec 16, 2024
Maintains: Overweight
Price Target: $100 → $110
Current: $97.32
Upside: +13.03%
Dec 12, 2024
Maintains: Overweight
Price Target: $280 → $330
Current: $309.12
Upside: +6.76%
Nov 5, 2024
Initiates: Overweight
Price Target: $32
Current: $12.64
Upside: +153.16%
Oct 30, 2024
Maintains: Overweight
Price Target: $30 → $40
Current: $34.81
Upside: +14.91%
Oct 25, 2024
Maintains: Neutral
Price Target: $75 → $85
Current: $67.05
Upside: +26.77%
Sep 9, 2024
Initiates: Neutral
Price Target: $90
Current: $76.56
Upside: +17.55%
Aug 8, 2024
Maintains: Neutral
Price Target: $53 → $50
Current: $32.02
Upside: +56.15%
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $6.36
Upside: +25.79%
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $256.06
Upside: -2.37%
Dec 20, 2023
Maintains: Neutral
Price Target: $10 → $16
Current: $18.94
Upside: -15.52%
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $8.65
Upside: -19.08%
Feb 23, 2023
Maintains: Neutral
Price Target: $15 → $17
Current: $15.20
Upside: +11.84%
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $134.59
Upside: -12.33%
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $175.61
Upside: -11.17%
Dec 17, 2021
Downgrades: Neutral
Price Target: $130 → $105
Current: $97.70
Upside: +7.47%
May 5, 2020
Maintains: Neutral
Price Target: $55 → $40
Current: $87.41
Upside: -54.24%